FDA FINANCIAL DISCLOSURE REG WOULD NOT APPLY TO PRECLINICAL
This article was originally published in The Gray Sheet
Executive SummaryFDA FINANCIAL DISCLOSURE REG WOULD NOT APPLY TO PRECLINICAL or manufacturing and controls studies, according to the agency's proposed rule, "Financial Disclosure by Clinical Investigators," published in the Federal Register Sept. 22. "FDA has tentatively chosen not to seek information on investigators carrying out preclinical or manufacturing and controls operations," the notice states.
You may also be interested in...
Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Here's what one researcher in the area, Steven Raman, had to say about the new options.
Novartis’s first digital innovation hub in Asia is launched in India, where the Swiss company hopes to ally with partners to deliver digital solutions for patients at scale.
Senate Finance Committee’s approach to penalize companies for raising WAC list prices is not a ‘price control,’ but a reasonable approach to change the incentives that distort pricing in the supply chain, US HHS Secretary Alex Azar says.